• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    The Changing Face of Medtech Surface Treatment

    The Totally Tubular Technologies that Support Medical Devices

    Simply Stimulating: Examining the Neurostimulation Sector

    Sensing Technology Drives the Future of Medical Care

    New and Developing Diabetes Technologies Offer 'Sweet Relief'
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    FDA Approves Abbott's Epic Max Tissue Valve for Aortic Valve Disease

    Aural Analytics' Speech Analytics Software for ALS Gains Breakthrough Status

    Bigfoot Biomedical Acquires Insulin Titration Algorithm from McGill

    Apply Now: Junkosha's Technology Innovator of the Year Awards 2023

    SIS Medical's OPN NC PTCA Dilatation Catheter Released in U.S.
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    The Changing Face of Medtech Surface Treatment

    The Totally Tubular Technologies that Support Medical Devices

    Simply Stimulating: Examining the Neurostimulation Sector

    Sensing Technology Drives the Future of Medical Care

    New and Developing Diabetes Technologies Offer 'Sweet Relief'
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Timeline Mystery for Updated EtO Rules

    An Update on Hospital Trends Post-Pandemic

    Don’t Fear the Audit: Benefits of Good Quality Practices

    Understanding the FDA’s Standards & Conformity Assessment Program

    Medtech Divestitures Are Good for Medtech Innovation
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    JBC Technologies

    Forefront Medical Technology

    Halkey-Roberts Corporation

    NDH Medical Inc.

    Providence Enterprise USA Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Designing for Manufacturing: 5 Common Startup Mistakes (and How to Avoid Them)

    5 Challenges Medtech Must Address to Transform Healthcare

    3D Printing Medical Devices Revolutionized Manufacturing

    5 Current Trends in Medical Device Security

    How Advanced Sensors Improve Design & Functionality of Respiratory Care Equipment
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    JBC Technologies

    Forefront Medical Technology

    Halkey-Roberts Corporation

    NDH Medical Inc.

    Providence Enterprise USA Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    The Buck Starts Here

    ...

    The Buck Starts Here
    Steve Maylish, Chief Commercial Officer, Fusion Biotec, and Ben Bobo, CEO, NeuroTemp LLC06.06.17
    Commercialization is the confluence of all prior activities, a time of high investment and high anxiety. Here the rubber meets the road—yet for a new device, visibility on that road is often quite poor. A regulatory agency approved your device for sale, but how do you get traction? If you build it (to meet your pricing target), will they come?

    Although established medical device companies have a more predictable path, product commercialization brings risk and uncertainty. Go-to market strategies often resemble a slog in the fog rather than a well-executed plan. Companies pull familiar levers of market research, product design, and clinical trials. Marketing applies the leverage of key opinion leaders (KOLs), Centers of Excellence (COE), peer-reviewed journals, clinical partners, and voice of the customer to maximize the offering’s impact and drive commercial certainty up and down corporate structure. However, according to a survey of 2,240 executives from McKinsey Global, only 39 percent feel confident in their company’s ability to commercialize a medical device. Commercialization is truly an art form; no one product, market, or customer acts predictably to the traditional commercial levers.

    In reality, no one can predict whether a product will be successful and become standard of care. The unreasonable pressure executives endure to deliver a revenue- producing product under budget and under schedule adds to this dynamic. Most of the mistakes that cost investors millions, significantly dilute key shareholders, hurt stock prices, and run startups out of business are made here. Commercialization is the culmination of a dream to deliver a disruptive and breakthrough medical device, but innovators, inventors, and engineers can fail to adequately filter ideas and designs through the most important element—the customer. Teams can fall victim to “drinking their own Kool-Aid” or to the pressure of executing the plan and miss the basics of product development.

    Presuming market research identified a unique clinical problem to solve with large market potential and a disruptive design approach, the Customer Requirements Document (CRD) is the greatest determinant of a successful commercial launch. The CRD provides specifications of what the customer wants the product to do in a clinical environment, based on their understanding of the technology. The Product Requirements Document (PRD) provides all the engineering requirements for what the product should do.

    When the CRD and PRD are misaligned, the product may not achieve commercial liftoff. The initial CRD and PRD provide a line in the sand to start development. However, these are living documents that evolve during the development process—expect them to evolve as KOLs interact with the device and provide feedback. Too often, this feedback occurs late in the process. This should change because of the new U.S. Food and Drug Administration (FDA) usability requirements. (Some of these new requirements are outlined in my article entitled “The Human Factor” in the May issue of MPO.)

    These evolving product features and iterations will, however, be in direct conflict with budgets, timelines, and expectations of executives and investors. The process can be cut short as undue pressure is applied; the product has a higher chance of failing in the clinical setting in these cases. An experienced R&D leader should provide a buffer between the development and executive teams. Investors will espouse—and project leaders will confirm—that projects usually take twice as long and cost twice as much as initially expected. This reality is often based on tasks unknown during budgeting and the discovery process of development. Project plans show milestones and a waterfall process, but feedback and iteration underlie the entire process.

    No one is prepared when a product misses its clinical mark during clinical studies. The design can be prototyped and tested, but the team can still fail to appreciate the impact of environmental factors on their design, customer requirements, or the technology’s failure to deliver on its promise. Since iterating the design at the end of development is expensive and time consuming, many assume clinical problems will be solved with enough training and education.

    One company developed a novel non-invasive monitoring technology and spent six years and over $12 million on a design unsuitable for the ICU environment and an accuracy that would never be clinically acceptable. Had the company invested in early prototypes with leading neurosurgeons and nurses, their understanding of the customer requirements and target the design needed to hit would have been dramatically different. This is the innovator’s dilemma: not listening to the customer/user throughout the process.

    Throughout the product development process, “commercialization” activities happen in parallel. These can be as varied as human factors, design for manufacturing, or clinical testing. The main factor in determining the market for a new device is identifying an unmet clinical need for a procedure, or a step in a procedure. Some companies are formed by an idea looking for an application. It’s far better to start with an unmet clinical need.

    For example, one company pioneered beating heart surgery. The unmet clinical need in this case was preventing patients from undergoing open-heart surgery on a heart/lung machine and avoiding the deleterious effects of cardiopulmonary bypass. The result: the company took 20 percent of the coronary artery bypass market and was sold for $313 million.

    There is a huge difference between how a large established medical device (LEMD) company and a start-up launches a product. A LEMD has established sales channels (40- to 200-person sales forces), KOLs, and an established brand name for product quality. They also have established national accounts that can be leveraged to promote the product into leading centers. Even with these built-in advantages, LEMDs still take a conservative approach to product introductions to customers.

    Typically, they identify thought leader sales representatives (TLRs) in their organizations that influence the sales teams. They target COEs in territories of TLRs to initiate the product launch with the purpose of developing sales messaging and “recipes for success.” Twenty to twenty five centers may be targeted in this phase to flesh out the price, promotion, and positioning of the product in the customer’s mind. Usually four to six months afterward, they will do a market release with the full sales organization. The TLRs will be active in this phase to lend credibility and gravitas to the product launch.

    Startups have a different challenge. They lack a brand name, national accounts, a distribution channel of sales pros with KOLs, and sometimes funding. A startup has two distinct options to develop its sales channel. First is a direct sales force, which brings the advantage of controlling the sales strategy. Going direct is expensive and adds dramatically to the burn rate. This can materially impact the company’s operations if the product is not ready for launch. Most startups do not have the luxury to add an eight- to 10-person sales team. Experienced, successful sales reps are highly paid, but inexperience doesn’t get you through the door.

    Identifying and training independent distributor sales reps to sell and promote the product is another option. However, the decision to use distributor reps should not be made for purely financial reasons. If the distributor reps also promote products with shorter sales cycles and minimal levels of approval, the startup can lose control of their strategy. It’s easy to feel abandoned; distributors typically have multiple products in their bag.

    Startup medical device companies passionately usher in new technology while facing the challenges of funding, development, and regulatory agencies in order to change the market and bring life-saving technology to patients in need. It may have taken at least 24 grueling months to get to product launch, but the distributor doesn’t have skin in the game and is often fixated on products driving short sales cycles and quick payment.

    When considering a distributor strategy, consider the sales cycle of your product and ensure you identify distributors comfortable working a six- to nine-month process. If your product isn’t ready for commercial release, distributors will focus on products creating a path to commissions.

    At this point, hindsight is 20/20. The distributors have given the ultimate gift of feedback—because in commercial terms, one only gets a couple of bites at the apple to make an impression in the marketplace. It’s hard to make a second impression (and recover with subsequent launches) if the product rollout looks half-baked, with a technology faltering out of the gate. Unfortunately, modifying a design can also mean resubmitting to the FDA.

    As sales falter, inventory grows. This ties up cash. Investing too much in inventory or factory automation before product launch increases company risk, even if it reduces unit cost. Additionally, as sales increase, manufacturing is strained. This problem is solvable—scaling manufacturing should be carefully timed with the product rollout. Manual manufacturing processes can provide flexibility during commercialization, but there should also be a quick and clear path to ramp when needed.

    Once the essentials are covered, the company must consider the estimated usage per institution. This bottom-up approach provides a more accurate sales forecast. When converting an institution, understand the competition and any existing group purchasing organization (GPO) contracts needing circumvention.

    GPOs and integrated delivery networks (IDN, a system of providers) control much of the decision-making for capital equipment. A healthy GPO and IDN strategy must exist. According to Definitive Healthcare, 97 percent of hospitals are affiliated with GPOs. The Healthcare Supply Chain Association also suggests GPOs manage about 72 percent of the purchases in hospitals.

    U.S. health data based on the U.S. Centers for Medicare and Medicaid Services found from 2013 to 2022, GPOs are expected to generate savings of up to $864 billion for the U.S. health system and their members. GPOs like Premier and Vizient together supply close to 1 million hospital beds. Vizient alone represents almost $100 billion in annual purchasing volume, but don’t assume members are loyal to a corporate contract. More than ever, cost containment and patient outcome data is crucial to survival.

    Almost 80 percent of institutional C-Suite executives have resource utilization programs in place to control the use of supplies and services. Value analysis committees delay the introduction of new products because each potential entrant must be vetted. Companies need to articulate the product’s measurable value, then prove it. If not, new devices will be commoditized (resulting in a lower price) or never purchased. They also have to be creative—for example, through an equipment lease, pay-per-use agreement, or risk-based contracts. Companies also need to know which contracting approaches provide institutional customers the most value.

    Obsess over customer feedback during the development phase and embrace negative input. If treated and handled correctly, each negative pearl is worth millions in valuation potential. Throughout the development process, keep an open mind, engage the customer often, and be willing to make changes. Solving a unique clinical problem in close coordination with the customer often results in a disruptive design approach. Hiring the right sales team to sell the right product is the only way to clear some fog on the road ahead. Once this is done, don’t underestimate the value of a comprehensive sales strategy. Commercialization will always be a time of high anxiety, but there’s no quicker road to success than taking the time to do it right. 


    Steve Maylish has been part of the medical device community for more than 30 years. He is currently chief commercial officer for Fusion Biotec, an Irvine, Calif.-based contract engineering firm that brings together art, science, and engineering to create medical devices. Early in his career, Maylish held positions at Fortune 100 corporations such as Johnson & Johnson, Shiley, Sorin Group, Baxter Healthcare, and Edwards Lifesciences.

    Ben Bobo is a senior medical device/healthcare technology executive with experience as a CEO, CCO, and COO. His background includes extensive sales and marketing successes in VC-funded start-up, early commercial stage, and multibillion-dollar corporate environments. Bobo has held positions with Edwards Lifesciences, Cardio Thoracic Systems, Guidant, and CardioVention. He has a BS in economics and an MBA from the University of Phoenix.
    Related Searches
    • commercialization
    • edwards
    • development
    • heart
    Related Knowledge Center
    • R&D & Design
    Suggested For You
    MEDICAL & BIOTECH MANUFACTURING MEDICAL & BIOTECH MANUFACTURING
    Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    Accu-Tube Appoints Matthew Haddle as CEO Accu-Tube Appoints Matthew Haddle as CEO
    Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    CE Mark Granted to Predictive Software for Kidney Allograft Survival CE Mark Granted to Predictive Software for Kidney Allograft Survival
    Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Precision Coating Merges with N2 Biomedical Precision Coating Merges with N2 Biomedical
    Presidio Medical Names Michael Onuscheck as CEO Presidio Medical Names Michael Onuscheck as CEO
    Medical Devices Market to Top $671.49 Billion by 2027 Medical Devices Market to Top $671.49 Billion by 2027
    Indago Announces $10 Million Financing Close and Name Change Indago Announces $10 Million Financing Close and Name Change
    Molli Surgical Molli Surgical's Breast Tumor Marker
    Vertigo Treatment Receives FDA Breakthrough Device Designation Vertigo Treatment Receives FDA Breakthrough Device Designation
    RapidPulse Closes $15 Million Series A Financing RapidPulse Closes $15 Million Series A Financing
    Midwest Products & Engineering Acquires MindFlow Design Midwest Products & Engineering Acquires MindFlow Design
    Vicarious Surgical Opens New Corporate Headquarters in Massachusetts Vicarious Surgical Opens New Corporate Headquarters in Massachusetts

    Related Literature / Brochures

    • MEDICAL & BIOTECH MANUFACTURING

      ISO 13485:2016 • FDA Registered

    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Neela Paykel is serving as general counsel and Tom Teisseyre assumes the chief product officer position.
      Business Wire 09.22.21

    • Tubing & Extrusion
      Accu-Tube Appoints Matthew Haddle as CEO

      Accu-Tube Appoints Matthew Haddle as CEO

      Haddle has a track record of leading organizations through strategic expansions across the medical device, aerospace, and industrial sectors.
      Accu-Tube 09.22.21


    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      The two deals will strengthen Heraeus' healthcare and medtech portfolio.
      Heraeus 09.22.21

    • CE Mark Granted to Predictive Software for Kidney Allograft Survival

      CE Mark Granted to Predictive Software for Kidney Allograft Survival

      Algorithm gives the probability the graft will still be functional at three, five, and seven years after evaluation by a healthcare professional.
      Cibiltech 09.21.21

    Loading, Please Wait..

    Trending
    • Medinbox And Abbott Partner To Increase Efficiency In Electrophysiology Labs
    • Masimo Reveals Freedom Health-Tracking Smartwatch
    • FDA OKs FemDx Medsystems' FalloView Device
    • Getinge’s Cardiosave Faces CE-Certificate Suspension From TÜV SÜD
    • A New Approach To Post-Market Surveillance
    Breaking News
    • FDA Approves Abbott's Epic Max Tissue Valve for Aortic Valve Disease
    • Aural Analytics' Speech Analytics Software for ALS Gains Breakthrough Status
    • Bigfoot Biomedical Acquires Insulin Titration Algorithm from McGill
    • Apply Now: Junkosha's Technology Innovator of the Year Awards 2023
    • SIS Medical's OPN NC PTCA Dilatation Catheter Released in U.S.
    View Breaking News >
    CURRENT ISSUE

    March 2023

    • Sensing Technology Drives the Future of Medical Care
    • New and Developing Diabetes Technologies Offer 'Sweet Relief'
    • Discussing Matters of Substance in Medtech Materials
    • Medical Device Testers Are Caught Up in a Whirlwind
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kemin Human Nutrition & Health Acquires Oral Health Ingredient
    Wiley Eliminates Outer Carton From Packaging to Reduce Waste
    ACG Expands as Vantage Nutrition Acquires ComboCap and its Dual-Chamber Capsule Technology
    Coatings World

    Latest Breaking News From Coatings World

    PPG Names Rodolfo Ramirez GM, Packaging Coatings
    Sherwin-Williams Unveils High Performance Interior Marine Decking Systems
    AkzoNobel Appoints Ricardo Rosso as Pontiac Site Manager
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA Approves Abbott's Epic Max Tissue Valve for Aortic Valve Disease
    Aural Analytics' Speech Analytics Software for ALS Gains Breakthrough Status
    Bigfoot Biomedical Acquires Insulin Titration Algorithm from McGill
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Thermo Fisher, Arsenal Biosciences Partner to Manufacture Autologous T-Cell Therapies
    Aquestive Therapeutics Expands Libervant License/Supply Agreement with Pharmanovia
    OncoVent, Orient EuroPharma Enter License Agreement for Oregovomab
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    GK Launches Vegan Hair Styling Range
    Sexual Wellness Brand Playground Recruits Christina Aguilera
    Buttah Skin Founder Wins Emerging Brand Partner of the Year Award from Macy’s
    Happi

    Latest Breaking News From Happi

    Indie Personal Care and Skincare Brand Indigo Wild Mainstreams Geranium-Patchouli Scent
    Kao Launches Space Shampoo Sheet for Haircare
    Procter & Gamble Brings Tide Relief Project to Mississippi Tornado Victims
    Ink World

    Latest Breaking News From Ink World

    INX International Makes Investment in Gooten
    Videojet Launches 1580 C Soft-Pigmented Contrast Printer
    Epson to Showcase Textile, Signage and Aqueous Printers at ISA 2023
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    AWA announces first International Linerless Label Conference
    Apex partners with MicroDynamics for anilox quality control
    Industrias Omega adds Durst Tau RSC E
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Toray Awarded for Nanodesign Technology
    SharpCell Launches Plastic-free Airlaid Material for Premium Napkins
    Suominen Offers Biolace Ultrasoft
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Collagen Matrix Rebrands to Regenity Biosciences
    OsteoBoost Study Yields Positive Results
    Conventus Flower Ortho Appoints Jeff Culhane as COO
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Universal Display Sponsors, Presents at ICDT 2023
    Miron Washington Joins Impinj Board of Directors
    All-Time High for Global 300MM Semiconductor Capacity in 2026: SEMI

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login